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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disease that is clinically characterized by progressive
cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are
the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes.
Methods: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has
implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains,
including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses.
Results: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations,
whereas PSEN1 c.379_382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity.
Conclusions: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled
in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful
clinical outcomes.
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Background
Alzheimer’s disease (AD) is characterized clinically by
progressive cognitive decline and neuropathologically by
progressive neuronal loss and the accumulation of amyl-
oid plaques and neurofibrillary tangles. Mutations in
amyloid-β precursor protein (APP), presenilin 1 (PSEN1)
and presenilin 2 (PSEN2) are the pathogenic cause of
autosomal dominant AD (ADAD). More than 200
pathogenic mutations have been identified in APP,
PSEN1, and PSEN2 (reviewed in [1, 2]). PSEN1 and
PSEN2 form the catalytic domain of the γ-secretase
complex, which is involved in sequential cleavage of
APP into amyloid-β (Aβ) peptides.
The Dominantly Inherited Alzheimer Network (DIAN)
is an observational study designed to follow families with
mutations in APP, PSEN1, and PSEN2 that cause ADAD
[3]. The DIAN Expanded Registry (DIAN EXR;
www.dianexr.org) is a web-based registry with global
outreach to ADAD families and investigators. It func-
tions to identify families with ADAD and to determine the
causative mutations through a genetic discovery program.
This program includes genetic counseling and testing for
known and unknown causes of ADAD. During a period of
6 years (2011 to 2017), the DIAN Clinical/Genetics com-
mittee reviewed 150 pedigrees, 76 of which were approved
for genetic counseling and testing. Forty-six probands
were positive for a coding variant in APP, PSEN1, or
PSEN2, including 39 individuals with known pathogenic
mutations, 6 with variants of unknown pathogenic signifi-
cance, and 1 variant that was determined to be an AD risk
factor.
In some cases, families are identified with several gener-
ations of early-onset AD; however, at the time of enroll-
ment, whether a pathogenic mutation is the cause of
disease in these families remains unknown. We performed
genetic analyses in research participants from six densely
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affected early-onset AD pedigrees and identified variants
in APP, PSEN1, and PSEN2 with unknown pathogenicity.
In all families examined, we lacked sufficient genetic
material to perform segregation analyses (e.g., DNA was
available from only one or two family members). To assess
the pathogenicity of novel variants in APP, PSEN1, and
PSEN2 when pedigree and clinical data are limited or
incomplete, Guerreiro and colleagues [4] proposed a
pathogenicity algorithm. In the present study, we modified
and expanded this algorithm to evaluate the pathogenicity




Genomic DNA was extracted from peripheral blood lym-
phocytes using standard protocols. All coding exons in
APP, PSEN1, and/or PSEN2 were amplified and sequenced
using the BigDye Terminator version 3.1 cycle sequencing
kit (Life Technologies, Carlsbad, CA, USA) and analyzed
on an ABI 3500 genetic analyzer (Life Technologies).
Sequence analysis was performed using Sequencher soft-
ware (Gene Codes, Ann Arbor, MI, USA).
Bioinformatics
To determine whether APP, PSEN1, and PSEN2 variants
represented rare or common polymorphisms, we investi-
gated two population-based exome sequencing databases:
the Exome Variant Server (EVS) and Exome Aggregation
Consortium (ExAC) browser. Polymorphism phenotype
v2 (PolyPhen-2; [5]) and Sorting Intolerant From Tolerant
(SIFT) were used to predict whether the amino acid
change would be disruptive to the encoded protein.
Cerebrospinal fluid
Cerebrospinal fluid (CSF) was collected by lumbar punc-
ture under fasting conditions from the PSEN1 M84V
carrier and noncarrier. CSF Aβ42, total tau, and tau
phosphorylated at threonine 181 (p-tau181) were mea-
sured by immunoassay (xMAP; Luminex, Austin, TX,
USA) as previously described [6].
PiB imaging
Structural magnetic resonance imaging (MRI) was per-
formed using 3-T scanners and following the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) protocol [7, 8].
T1-weighted scans were processed through FreeSurfer.
Positron emission tomography with Pittsburgh com-
pound B (PiB) was coregistered with MRI images. The
standardized uptake value ratio (SUVR) was calculated
for each region [9, 10]. Global burden was characterized
using a summary measure [9]. These data were collected
for a PSEN1 M84V carrier and noncarrier.
Biochemical analysis
Plasmids and mutagenesis
The full-length PSEN1 complementary DNA (cDNA) was
cloned into pcDNA3.1 Myc/His vector [11]. The M84V,
c.379_382delXXXXinsG, or A396T variant was introduced
into the PSEN1 cDNA using the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA, USA). Clones were sequenced to confirm the
presence of the variant and the absence of additional modi-
fications. PSEN1 wild type (WT) and the pathogenic PSEN1
A79V mutation were included as controls.
The full-length PSEN2 cDNA was cloned into
pcDNA3.1 vector [12]. The L238F or R284G variant was
introduced into the PSEN2 cDNA and screened as de-
scribed above. PSEN2 WT and the pathogenic PSEN2
N141I mutation were included as controls [13].
The full-length APP cDNA (isoform 695) was cloned
into pcDNA3.1 [14]. The T719N variant was introduced
into the APP cDNA and screened as described above.
APP WT and the pathogenic APP KM670/671NL(Swe)
mutation were included as controls.
Transient transfection
To assess novel PSEN1 and PSEN2 variants, we used
neuroblastoma cells (N2A) stably expressing human
APP WT (695 isoform; N2A695). To assess novel APP
variants, we used N2A. N2A cells were maintained in
equal amounts of DMEM and Opti-MEM, supple-
mented with 5% FBS, 2 mM L-glutamine, 100 μg/ml
penicillin/streptomycin, and, for stable cells, 200 μg/
ml G418 (Life Technologies). Upon reaching confluence,
cells were transiently transfected with Lipofectamine
2000 reagent (Life Technologies). Culture media were
replaced after 24 hours, and cells were incubated for
another 24 hours prior to analysis. Four independent
transfections were performed for each construct and
used for subsequent analyses.
Aβ enzyme-linked immunosorbent assay
Conditioned medium was collected and centrifuged at
3000 × g at 4 °C for 10 minutes to remove cell debris. The
levels of Aβ40 and Aβ42 were measured in cell culture media
by sandwich enzyme-linked immunosorbent assay (ELISA)
as described by the manufacturer (Life Technologies). To
account for variability in transfection efficiency between
experiments, ELISA values were obtained (pg/ml) and cor-
rected for total intracellular protein (μg/ml). Statistical
difference was measured using an unpaired Student’s t test.
Results and discussion
PSEN1 M84V
The proband was identified in a family with three gener-
ations of early-onset AD and with a mean age at onset
of 59 years (Fig. 1; pedigree not shown to avoid
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disclosing mutation status to asymptomatic proband and
other family members). Sequencing of the proband
revealed a single base substitution (ATG to GTG) at
codon 84 in exon 4 of PSEN1, resulting in a
methionine-to-valine change (M84V). PSEN1 M84V was
also identified in a family-based sequencing study of AD
(National Institute of Mental Health Alzheimer’s Disease
Genetics Initiative Study) [15]. Two PSEN1 M84V car-
riers were confirmed to have had AD at autopsy with
ages at symptomatic onset of 70 and 72 years. The third
carrier was cognitively normal at age 67 years [15].
To determine whether PSEN1 M84V represents a rare
polymorphism, we examined two population-based
exome sequencing databases (Table 1). PSEN1 M84V
was absent from both EVS and ExAC. PSEN1 M84L was
identified in one individual in the ExAC browser. PSEN1
M84V was also absent in more than 1700 AD and con-
trol samples with whole-exome sequencing.
CSF Aβ, total tau, and phosphorylated tau were measured
in the PSEN1 M84V carrier, who was cognitively normal at
the time of lumbar puncture. CSF Aβ (361.5 pg/ml),
total tau (84.93 pg/ml), and p-tau181 (22.02 pg/ml) at
11 years prior to the parental age at symptomatic onset
was consistent with other presymptomatic pathogenic
mutation carriers but not completely distinct from non-
carriers [3, 6]. The PSEN1 M84V carrier produced a mean
cortical PiB SUVR value of 1.132 at 15 years prior to the
parental age at symptomatic onset and 1.209 at 11 years
prior to parent age of disease onset (Fig. 2). A related non-
carrier was imaged at 16 years prior to the parent age of
disease onset and produced mean cortical PiB SUVR
values of 1.086 and 1.039 at 13 years prior to age at dis-
ease onset in the parent (Fig. 2). Thus, fluid and imaging
biomarkers were consistent with those observed in pre-
symptomatic ADAD mutation carriers.
We next sought to determine whether the PSEN1
M84V variant alters Aβ isoform levels in a manner
consistent with previously reported pathogenic PSEN1
mutations. We expressed vectors containing PSEN1 WT,
A79V (a known pathogenic mutation), and M84V in
N2A695 cells. We found that cells expressing PSEN1
M84V produced significantly more Aβ42 than cells
expressing PSEN1 WT (Fig. 3a–c). We also observed a
significant increase in the Aβ42/Aβ40 ratio in cells ex-
pressing PSEN1 M84V or the pathogenic PSEN1 A79V-
compared with PSEN1 WT-expressing cells (Fig. 3c).
Thus, we can apply a pathogenicity algorithm, modi-
fied from Guerreiro and colleagues [4], to assess the
pathogenicity of PSEN1 M84V (Fig. 4). PSEN1 M84V
occurs within exon 4 and the first transmembrane do-
main. This residue is highly conserved between PSEN1
and PSEN2 [16]. Additionally, a pathogenic mutation
has been reported at this site: ΔI83/M84 [17, 18]. In a
cell model, Aβ levels were consistent with pathogenic
mutations (Fig. 3a–c, g). Thus, PSEN1 M84V satisfies all
criteria for pathogenicity based on residue and Aβ levels
[4]. Taken together, we propose that PSEN1 M84V rep-
resents a pathogenic mutation.
PSEN1 A396T
The proband was identified in a family with three gener-
ations of early-onset AD (Fig. 1a). The proband had an
age at symptomatic onset of 50 years. The parent of the
proband had an age at symptomatic onset of 57 years,
with AD confirmed at autopsy at age 67 years. Sequen-
cing of the proband (Fig. 1a) revealed a single base sub-
stitution (GCG to ACG) at codon 396 in exon 11 of
PSEN1, resulting in an alanine-to-threonine change
(A396T). This variant was reported previously in one
individual with sporadic AD [19]. PSEN1 A396T was
absent in the EVS and ExAC databases (Table 1). We
found that cells expressing PSEN1 A396T produced sig-
nificantly more Aβ42 than cells expressing PSEN1 WT
(Fig. 3a–c). Thus, applying the algorithm for assessing
pathogenicity (Fig. 4), we propose that the PSEN1
A396T represents a probable pathogenic mutation.
PSEN1 c.379_382delXXXXinsG
The proband had an age at symptomatic onset of
50 years, with an average age at symptomatic onset in
family members aged 43 years (Fig. 1b). Sequencing of
a b
c d e
Fig. 1 Identification of APP, PSEN1, and PSEN2 variants in densely
affected Alzheimer’s disease (AD) pedigrees. a–e Pedigrees. Half-shaded
triangles represent individuals with a clinical diagnosis of symptomatic
AD. Fully shaded triangles represent individuals with autopsy-confirmed
symptomatic AD. Diagonal lines represent deceased individuals. Arrows
indicate those individuals with DNA, all of whom are mutation/variant
carriers. Pedigrees have been masked to maintain anonymity. The
pedigree of the PSEN1 M84V family was excluded to prevent potential
disclosure of mutation status in asymptomatic mutation carriers
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Table 1 Bioinformatic analysis of APP, PSEN1, and PSEN2 variants of unknown pathogenicity
Gene Variant EVSa ExACb PolyPhen SIFT Variant previously reported Location PSEN1-PSEN2 conservation
APP T719N 0 0 Probably
damaging
Damaging Yes Exon 17 N/A
PSEN1 M84V 0 0 Probably
damaging
Tolerated Yes Exon 4 (TM-1) Yes
PSEN1 c.379_382delXXXXinsG 0 0 N/A Tolerated No Exon 5 (HL1) Yes
PSEN1 A396T 0 0 Probably
damaging
Tolerated Yes Exon 11 (HL8) No
PSEN2 L238F 2 2 Probably
damaging
Damaging Yes Exon 7 (TM-V) Yes
PSEN2 R284G 0 0 Probably
damaging
Damaging No Exon 8 Yes
Abbreviations: PolyPhen Polymorphism phenotype, SIFT Sorting Intolerant From Tolerant, EVS Exome Variant Server, ExAC Exome Aggregation Consortium, PSEN
Presenilin, APP Amyloid precursor protein
aRepresents sequence data from 4300 unrelated European Americans (8598 alleles)
bRepresents sequence data from 60,706 unrelated European Americans (121,204 alleles)
Fig. 2 Pittsburgh compound B (PiB) uptake in the brain of a presymptomatic PSEN1 M84V carrier is consistent with presymptomatic autosomal
dominant Alzheimer’s disease mutation carriers. 11C-PiB positron emission tomographic scans were performed longitudinally in a PSEN1 M84V
noncarrier and carrier. The color scale for standardized uptake values (SUV) indicate red (high), yellow (medium), and blue (low) PiB retention. EYO
Estimated years of onset
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the proband (Fig. 1b) revealed a 4-bp deletion and inser-
tion of G at codon 127 in exon 5 of PSEN1, resulting in
the deletion of glutamine and arginine and insertion of
glycine (c.379_382delXXXXinsG). This is a novel variant
and was absent from the EVS and ExAC databases
(Table 1). N2A695 expressing PSEN1 c.379_382delXXX-
XinsG produced Aβ42 and Aβ40 levels similar to PSEN1
WT (Fig. 3a–c). Thus, we propose that PSEN1
c.379_382delXXXXinsG is an AD risk factor or benign
polymorphism.
PSEN2 R284G
The proband had an age at symptomatic onset of
58 years, with average age at symptomatic onset in the
family of 56 years (Fig. 1c). Sequencing of the proband
(Fig. 1c) revealed a single base pair substitution (CGG to
GGG) at codon 284 in exon 8 of PSEN2, resulting in
an arginine-to-glycine change (R284G). This is a novel
variant and was absent from the EVS and ExAC data-
bases (Table 1).
To assess the effects of PSEN2 variants on Aβ isoform
levels, we expressed vectors containing PSEN2 WT,
N141I, and R284G in N2A695 cells. Cells expressing
PSEN2 N141I and R284G produced significantly more
Aβ42 than cells expressing PSEN2 WT (Fig. 3d and e).
The Aβ42/Aβ40 ratio was also significantly higher in cells
expressing PSEN2 N141I and R284G (Fig. 3f ). Thus, ap-
plying the algorithm for assessing pathogenicity (Fig. 4),





Fig. 3 Amyloid-β 1–42 peptide (Aβ42) and Aβ40 in cells expressing APP, PSEN1, and PSEN2 variants of unknown pathogenicity. N2A695 cells were
transfected with vectors expressing presenilin 1 or 2. Media was replaced 24 hours posttransfection and incubated for an additional 24 hours.
Media were collected, and Aβ42 and Aβ40 were measured by enzyme-linked immunosorbent assay (ELISA) (pg/ml). Total intracellular protein was
measured by bicinchoninic acid assay and used to normalize to ELISA Aβ values, resulting in a value represented as pg/μg (see the Methods
section of text). a–c PSEN1 wild type (WT), pathogenic mutation A79V, and variants with unknown pathogenicity. a Aβ42. b Aβ40. c Aβ42/Aβ40
ratio. d–f PSEN2 WT, pathogenic mutation N141I, and variants with unknown pathogenicity. d Aβ42. e Aβ40. f Aβ42/Aβ40 ratio. g–i APP WT,
pathogenic mutation KM670/671NL(Swe), and APP T719N. Graphs represent the mean (±SEM) of four replicate experiments. * p < 0.05. PSEN1
QR127G is the amino acid representation for PSEN1 c.379_382delXXXXinsG
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PSEN2 L238F
The proband was identified in a family with three genera-
tions of early-onset AD (Fig. 1d). The proband had an age
at symptomatic onset of 49. The parent of the proband
was diagnosed with AD at 57 years of age and died at age
77. Sequencing of the proband (Fig. 1d) revealed a single
base pair substitution (CTT to TTT) at codon 238 in exon
7 of PSEN2, resulting in a leucine-to-phenylalanine
change (L238F). PSEN2 L238F was also identified in two
alleles in EVS, in two alleles in ExAC, and in one individ-
ual with sporadic AD (Table 1; [20]). CSF Aβ, total tau,
and phosphorylated tau were measured in a PSEN2 L238F
carrier related to the proband, who was cognitively normal
at the time of lumbar puncture. CSF Aβ (506.54 pg/ml),
total tau (38.75 pg/ml), and p-tau181 (21.33 pg/ml) at
17 years prior to the parental age at symptomatic onset
was consistent with biomarker levels in normal controls
[3, 6]. Cells expressing PSEN2 L238F produced Aβ42 and
Aβ40 levels similar to PSEN2 WT (Fig. 3d–f ). Thus, we
propose that PSEN2 L238F represents an AD risk factor
or benign polymorphism.
App T719N
The proband was identified in a family with two genera-
tions of early-onset AD (Fig. 1e). The proband had an
age at symptomatic onset of 45 years. The parent of the
proband was diagnosed at 45 years of age. Sequencing of
the proband (Fig. 1e) revealed a single base pair substitu-
tion (ACC to AAC) at codon 719 in exon 17 of APP,
resulting in a threonine-to-asparagine change (T719N).
APP T719N was absent in the EVS and ExAC databases
and was detected in one individual with early-onset AD
(Table 1) [21]. Cells expressing APP T719N produced
significantly elevated levels of Aβ42 and Aβ42/Aβ40 rela-
tive to APP WT (Fig. 3g–i ). Thus, we propose that APP
T719N is a probable pathogenic mutation.
Conclusions
By applying genetic, bioinformatic, and functional data
to an algorithm to assess pathogenicity, we propose that
the PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and
APP T719N are likely pathogenic mutations resulting in
ADAD, whereas PSEN1 c.379_382delXXXXinsG and
Fig. 4 Algorithm to classify the benign or pathogenic nature of APP, PSEN1, and PSEN2 variants. This model is modified from the algorithm previously
proposed by Guerreiro et al. in 2010 [4]. The modifications include the evaluation of variants in the Exome Variant Server and Exome Aggregation
Consortium databases and a tiered approach to evaluating functional studies that more heavily weighs the impact of the variant on amyloid-β 1–42
peptide (Aβ42) and Aβ40 levels on pathogenicity
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PSEN2 L238F are likely benign polymorphisms. This
algorithm was adapted and modified from a pathogen-
icity algorithm originally proposed by Guerreiro and col-
leagues [4]. We have expanded upon this algorithm in
several important ways: (1) expanding the number of
controls in the association analyses from 100 to 65,000
by exploiting the EVS and ExAC databases; (2) evaluat-
ing the bioinformatic functional findings (e.g., conserva-
tion between PSEN1 and PSEN2 and the presence of
other mutations at the same residue) independent of the
cell-based functional findings; and (3) incorporating
cell-based assays to evaluate the impact of novel variants
on Aβ levels. We propose that this modified approach to
assessing pathogenicity provides an important pipeline
for incorporating mutation data at several levels and that
this algorithm may be adapted to impute pathogenicity
when extensive genetic data are missing for affected
families. Designation of a variant as pathogenic will
allow individuals to enroll in observational and clinical
trials for AD, with clear applications in clinical and re-
search settings.
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